Program
QRX-3
Its studies are mostly in Acute Kidney Injury · Renal Insufficiency, Chronic · Diabetic Nephropathies, led by Ebima Clifford Okundaye.
Furthest: phase 3, since Mar 4, 20253 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ebima Clifford Okundaye | 32 open or running | phase 3since Mar 4, 2025 | Mar 4, 2025 | Dec 30, 2026phase 3 · NCT07161843 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 4, 2025First study: phase 3 study in Renal Insufficiency, ChronicFirst studyNCT06866236 · 3,000 planned · United States
- Apr 10, 2025Phase 3 study in Acute Kidney InjuryNCT07161843 · 500 planned · United States
- Apr 21, 2025Phase 2 study in Diabetic NephropathiesNCT06948292 · 127 enrolled · United States
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Acute Kidney InjuryNCT07161843
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06948292Diabetic Nephropathies · United States | 2 | Completed | Aug 30, 2024 | 127 |
| NCT07161843Acute Kidney Injury · United States | 3 | Not yet recruiting | Dec 30, 2026 | 500 |
| NCT06866236Renal Insufficiency, Chronic · United States | 3 | Not yet recruiting | Oct 2026 | 3,000 |
How it is read
Names in the registry
- “QRX-3”, 3 entries
Conditions, from the studies’ own filings
- Acute Kidney Injury, 1 study
- Renal Insufficiency, Chronic, 1 study
- Diabetic Nephropathies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.